von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.
Stroke is a leading cause of death and disability. The only therapy available is recombinant tissue plasminogen activator, but side effects limit its use. Platelets play a crucial role during stroke, and the inflammatory reaction promotes neurodegeneration. von Willebrand factor (VWF), an adhesion molecule for platelets, is elevated in patients with acute stroke. The activity of VWF is modulated by ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) that cleaves VWF to smaller less-active forms. We recently documented that ADAMTS13 negatively regulates both thrombosis and inflammation. We report that deficiency or reduction of VWF reduces infarct volume up to 2-fold after focal cerebral ischemia in mice, thus showing the importance of VWF in stroke injury. In contrast, ADAMTS13 deficiency results in larger infarctions, but only in mice that have VWF. Importantly, infusion of a high dose of recombinant human ADAMTS13 into a wild-type mouse immediately before reperfusion reduces infarct volume and improves functional outcome without producing cerebral hemorrhage. Furthermore, recombinant ADAMTS13 did not enhance bleeding in a hemorrhagic stroke model. Our findings show the importance of VWF in regulating infarction and suggest that recombinant ADAMTS13 could be considered as a new therapeutic agent for prevention and/or treatment of stroke.
Zhao
Bing-Qiao
BQ
Immune Disease Institute, Boston, MA 02115, USA.
Chauhan
Anil K
AK
Canault
Matthias
M
Patten
Ian S
IS
Yang
Janie J
JJ
Dockal
Michael
M
Scheiflinger
Friedrich
F
Wagner
Denisa D
DD
D051722:ADAM Proteins / Q000494:pharmacology*; D000071120:ADAMTS13 Protein; D000818:Animals; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000201:enzymology* / Q000235:genetics / Q000517:prevention & control*; D008666:Metalloendopeptidases / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D011994:Recombinant Proteins / Q000494:pharmacology; D020521:Stroke / Q000201:enzymology* / Q000517:prevention & control*; D014841:von Willebrand Factor / Q000235:genetics / Q000378:metabolism
D011994:Recombinant Proteins; D014841:von Willebrand Factor; D051722:ADAM Proteins; C502939:ADAMTS13 protein, mouse; D008666:Metalloendopeptidases; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human
Blood. 2009 Apr 9;113(15):3600-3
19182208
J Exp Med. 2006 Mar 20;203(3):767-76
16533881
Nat Med. 2006 Nov;12(11):1278-85
17072311
Eur J Pediatr. 2007 Mar;166(3):249-57
17187257
Thromb Haemost. 1999 Aug;82(2):938-46
10605807
Blood. 2008 Apr 1;111(7):3452-7
18083848
Circulation. 2007 May 1;115(17):2323-30
17438148
J Thromb Haemost. 2003 Jul;1(7):1335-42
12871266
Nat Med. 2006 Apr;12(4):441-5
16565723
J Clin Invest. 2005 Oct;115(10):2752-61
16200209
Blood. 2008 May 15;111(10):4958-64
18256319
Platelets. 1998;9(3-4):155-9
16793694
Stroke. 2006 Nov;37(11):2672-7
16990571
J Clin Invest. 2000 Aug;106(3):385-92
10930441
J Thromb Haemost. 2006 Jun;4(6):1186-93
16706957
N Engl J Med. 1998 Nov 26;339(22):1585-94
9828246
Blood. 2006 Dec 1;108(12):3746-52
16926295
Nat Med. 2003 Aug;9(8):1020-5
12858167
Br J Haematol. 2005 Apr;129(1):93-100
15801961
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9524-9
9689113
J Exp Med. 2008 Sep 1;205(9):2065-74
18695007
J Biochem. 2006 Jan;139(1):147-54
16428330
J Clin Invest. 1998 Oct 1;102(7):1301-10
9769322
J Cereb Blood Flow Metab. 2006 May;26(5):654-65
16121126
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):728-39
17272754
Blood. 1999 Jun 15;93(12):4277-83
10361125
Annu Rev Cell Biol. 1990;6:217-46
2275814
Neurology. 1999;53(7 Suppl 4):S3-14
10532643
N Engl J Med. 1998 Nov 26;339(22):1578-84
9828245
Annu Rev Med. 2005;56:173-91
15660508
J Clin Invest. 1996 Jan 15;97(2):493-500
8567972
Blood. 2008 Jul 1;112(1):11-8
18574040
Exp Neurol. 2007 Feb;203(2):555-67
17067578